title: p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with anthracycline-containing regimens.
authors.forename: A
authors.initials: A
authors.lastname: Bottini
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
authors.forename: A
authors.initials: A
authors.lastname: Bersiga
authors.forename: M P
authors.initials: MP
authors.lastname: Brizzi
authors.forename: A
authors.initials: A
authors.lastname: Berruti
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D023381:Endpoint Determination; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D015203:Reproducibility of Results; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
chemical_list: D016159:Tumor Suppressor Protein p53